Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis

NACompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Aortic Valve StenosisMyocardial Fibrosis
Interventions
DIAGNOSTIC_TEST

Echocardiography

Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.

DIAGNOSTIC_TEST

MRI

Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.

DIAGNOSTIC_TEST

Blood test

Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.

DIAGNOSTIC_TEST

ECG and Holter-ECG

ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.

DIAGNOSTIC_TEST

6 min walking test

6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.

Trial Locations (1)

Unknown

Department of Circulation and Medical Imaging, Trondheim

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

collaborator

Oslo University Hospital

OTHER

lead

Norwegian University of Science and Technology

OTHER

NCT03422770 - Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis | Biotech Hunter | Biotech Hunter